Your browser doesn't support javascript.
loading
Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology.
Kac, Przemyslaw R; González-Ortiz, Fernando; Emersic, Andreja; Dulewicz, Maciej; Koutarapu, Srinivas; Turton, Michael; An, Yang; Smirnov, Denis; Kulczynska-Przybik, Agnieszka; Varma, Vijay R; Ashton, Nicholas J; Montoliu-Gaya, Laia; Camporesi, Elena; Winkel, Izabela; Paradowski, Boguslaw; Moghekar, Abhay; Troncoso, Juan C; Lashley, Tammaryn; Brinkmalm, Gunnar; Resnick, Susan M; Mroczko, Barbara; Kvartsberg, Hlin; Gregoric Kramberger, Milica; Hanrieder, Jörg; Cucnik, Sasa; Harrison, Peter; Zetterberg, Henrik; Lewczuk, Piotr; Thambisetty, Madhav; Rot, Uros; Galasko, Douglas; Blennow, Kaj; Karikari, Thomas K.
Afiliação
  • Kac PR; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden. przemyslaw.kac@gu.se.
  • González-Ortiz F; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • Emersic A; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden.
  • Dulewicz M; Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.
  • Koutarapu S; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
  • Turton M; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • An Y; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • Smirnov D; Bioventix Plc, Farnham, GU9 7SX, UK.
  • Kulczynska-Przybik A; Brain Aging and Behavior Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.
  • Varma VR; Department of Neurosciences, University of California, San Diego, CA, 92161, USA.
  • Ashton NJ; Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, 15-269, Poland.
  • Montoliu-Gaya L; Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.
  • Camporesi E; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • Winkel I; Department of Old Age Psychiatry, King's College London, London, SE5 8AF, UK.
  • Paradowski B; Centre for Age-Related Medicine, Stavanger University Hospital, 4011, Stavanger, Norway.
  • Moghekar A; South London & Maudsley NHS Foundation, NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia, SE5 8AF, London, UK.
  • Troncoso JC; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • Lashley T; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • Brinkmalm G; Dementia Disorders Center, Medical University of Wroclaw, 59-330, Scinawa, Poland.
  • Resnick SM; Department of Neurology, Medical University of Wroclaw, 50-556, Wroclaw, Poland.
  • Mroczko B; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
  • Kvartsberg H; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
  • Gregoric Kramberger M; Department of Pathology, John Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
  • Hanrieder J; Department of Neurodegenerative diseases, UCL Queen Square Institute of Neurology, WC1N 1PJ, London, UK.
  • Cucnik S; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • Harrison P; Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA.
  • Zetterberg H; Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, 15-269, Poland.
  • Lewczuk P; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
  • Thambisetty M; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden.
  • Rot U; Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.
  • Galasko D; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Blennow K; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, 141 52, Huddinge, Sweden.
  • Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
Nat Commun ; 15(1): 2615, 2024 Mar 23.
Article em En | MEDLINE | ID: mdl-38521766
ABSTRACT
Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Here, we examined the diagnostic utility of plasma p-tau212. In five cohorts (n = 388 participants), plasma p-tau212 showed high performances for AD diagnosis and for the detection of both amyloid and tau pathology, including at autopsy as well as in memory clinic populations. The diagnostic accuracy and fold changes of plasma p-tau212 were similar to those for p-tau217 but higher than p-tau181 and p-tau231. Immunofluorescent staining of brain tissue slices showed prominent p-tau212 reactivity in neurofibrillary tangles that co-localized with p-tau217 and p-tau202/205. These findings support plasma p-tau212 as a peripherally accessible biomarker of AD pathophysiology.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Limite: Humans Idioma: En Revista: Nat Commun / Nature communications Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Limite: Humans Idioma: En Revista: Nat Commun / Nature communications Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia